Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy
Status
Conditions
Details and patient eligibility
About
Hemophilia is a constitutional coagulation disorder responsible for a hemorrhagic phenotype in patients from an early age. Hemarthrosis is one of the most frequent complications in hemophiliacs and leads to the development of severe and early arthropathy, sometimes as early as childhood. To date, there is no curative treatment for these joint disorders and preventive treatments are insufficient to completely prevent joint degradation. Mesenchymal stem cells have been shown to be of therapeutic interest in the management of pathologies such as osteoarthritis and inflammatory arthritis through their anti-inflammatory, regenerative and anti-apoptotic effects. Hemophilic arthropathy is a separate condition at the border of these two diseases Our study aim to show pre-clinical interest of mesenchymal stem cell therapy in hemophilic arthropathy
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Hemophilia A or B adult patient, with or without arthropathy
- Heathly control
Exclusion criteria
- Antiinflammatory drug use
- immunosuppressive treatment or condition
Trial contacts and locations
Loading...
Central trial contact
Alexandre THERON, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal